Belimumab for lupus erythematosus: Added benefit not proven

August 29, 2012

Belimumab (trade name Benlysta) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody is only considered as treatment when the disease is still active in spite of standard therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of this drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).

According to the findings, there is no proof that belimumab provides added benefit as the manufacturer's dossier does not contain any relevant studies for the assessment of added benefit.

Belimumab in comparison to optimized standard therapy

The Federal Joint Committee (G-BA) specified that the appropriate comparator therapy should be an optimized standard therapy with various drugs that have been approved in Germany. A (standard) therapy is said to be "optimized" when the treatment has been adapted to the individual patient with respect to tolerability, effect and clinical course. The dossier - or its assessment by IQWiG - was supposed to answer the question as to whether the additional administration of belimumab offers advantages in comparison with the optimization of standard therapy alone.

Adaptation of standard therapy was only possible in the studies to a limited extent

The manufacturer uses two approval studies in the dossier (BLISS52 and BLISS76). However, these are not suited to prove added benefit, as the study protocols inappropriately restricted the for adapting the standard therapy. In particular, the administration of glucocorticoids was explicitly restricted.

This restriction is a consequence of the intended purpose of these studies. In the main focus is on proving efficacy. If the adaptation of the standard therapy had not been restricted, the differences in the effects between the belimumab and comparator groups might have been smaller, or indeed totally absent.

A study design of this type is suitable for approval purposes, but not for a benefit assessment in accordance with § 35a Social Code Book (SGB) V, as the purpose of the latter is to determine added benefit in comparison to an alternative treatment option. According to the specifications of the G-BA for the specific case of belimumab, this is solely the optimization of standard therapy.

Relevant study excluded

On the one hand, the manufacturer argues on the basis of these two unsuitable studies in the dossier. On the other hand, another study (LBSL02) is explicitly excluded, even though optimization of the standard therapy was possible here. This study would have been relevant for the assessment. IQWiG cannot support the justification for excluding the study. Thus the pharmaceutical company has not presented any relevant studies or analyses of study data in its dossier.

G-BA decides on the extent of added benefit.

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure which can provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

Explore further: Added benefit of fampridine is not proven

Related Stories

Added benefit of fampridine is not proven

August 29, 2012
Fampridine (trade name Fampyra) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple ...

Added benefit of linagliptin is not proven

January 6, 2012
Linagliptin (trade name: Trajenta) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled ...

Abiraterone: Indication of considerable added benefit in certain patients

January 6, 2012
Abiraterone (trade name: Zytiga) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic ...

Collagenase for Dupuytren's contracture: Added benefit not proven

July 12, 2012
Collagenase extracted from Clostridium histolyticum (trade name: Xiapex) was approved in the beginning of 2011 for the treatment of people with Dupuytren's contracture. In an early benefit assessment pursuant to the "Act ...

Added benefit of eribulin in breast cancer is not proven

August 16, 2012
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

Cabazitaxel can offer an advantage in certain patients

May 29, 2012
Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.